BioUtah News
-
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
-
Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
-
Merit Medical Acquires Biolife Delaware
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of…
-
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
-
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
-
KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems
-
Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.
-
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.
-
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target…
-
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
-
EDWARDS TAVR RECEIVES FDA APPROVAL FOR PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Transforming Care for Severe AS Patients
-
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to…
-
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD
-
Biologic Input Output Systems (BIOS) Appoints Chris Duncan, MD as Chief Medical Officer to Drive Clinical Innovation
Renowned neuroprosthetics expert joins BIOS to lead clinical strategy and advance development of the Universal Neural Interface.
-
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
-
ARUP Launches pTau 217 Blood Test To Detect Alzheimer’s Disease Pathology
The biomarker pTau 217 is associated with Alzheimer’s disease pathology and can be detected in plasma, providing a…
-
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
-
Congresssional Staffer Tours
Congresssional Staffer Tours
-
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
-
Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
Salt Lake City, UT – April 9, 2025 – DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company…
-
BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD
Huntsman Cancer Institute at the University of Utah (the U) broke ground on its second Comprehensive Cancer Center…
-
The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors
Hutt Brings Decades of Regulatory Insight to Help Advance Nanoparticle Technology Platform SALT LAKE CITY, Utah (April 9,…
-
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading…
-
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia,…
-
Merit Medical Launches the Ventrax™ Delivery System
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia SOUTH JORDAN, Utah, April 09,…
-
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake…
-
G2G Consulting Provides Updates from Washington D.C.
G2G Consulting Provides Updates from Washington D.C.
-
Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City
BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake…
-
bioMérieux Recognized as Top 1% by S&P Global
bioMérieux Recognized as Top 1% by S&P Global
-
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
-
bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO
Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics,…
-
E&I Ski Day 2025 Recap
E&I Ski Day 2025 Recap
-
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
-
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/…
-
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
-
First Patient Enrolled in Merit Medical’s PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent…
-
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
-
Altitude Lab Demo Day
As part of BioHive week, Altitude Lab hosted its annual Demo Day.
-
Steve Pacelli Appointed CEO of Epitel, Inc.
Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth
-
Sera Prognostics Announces Pricing of $50 Million Public Offering
Sera Prognostics Announces Pricing of $50 Million Public Offering
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8M Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial…
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
